静注硝普钠都无效 如此顽固的高血压您见过吗?

2018-03-29 佚名 环球医学

女性40岁,以“高血压伴阵发性头痛4年、反复晕厥1年”于2004年9月6日入院。患者4年前(2000年)发现血压增高伴头痛,阵发性加剧,就诊于当地医院,测血压最高240/120mmHg,诊为“高血压”,口服卡托普利,普萘洛尔(具体不详),血压控制不良。1年前(2003年)无明显诱因症状加重,反复出现头痛、恶心、心悸,多次晕厥,于当地医院治疗效果欠佳,来我院急诊。

女性40岁,以“高血压伴阵发性头痛4年、反复晕厥1年”于2004年9月6日入院。患者4年前(2000年)发现血压增高伴头痛,阵发性加剧,就诊于当地医院,测血压最高240/120mmHg,诊为“高血压”,口服卡托普利,普萘洛尔(具体不详),血压控制不良。1年前(2003年)无明显诱因症状加重,反复出现头痛、恶心、心悸,多次晕厥,于当地医院治疗效果欠佳,来我院急诊。

入急诊后反复发作头痛、头晕伴面色苍白、出汗,血压发作性增高达250/150mmHg,心率达170次/分,反复发生一过性晕厥,数分钟后缓解,应用硝普钠200μg/ min、酒石酸美托洛尔5mg/min静脉泵入,血压无明显下降,改用盐酸乌拉地尔500μg/min静脉泵入,血压趋于稳定,最低可降至120/80mmHg,为进一步诊治于2004年9月9日转入高血压中心。

体格检查

体温36.0℃,脉搏110次/分,呼吸18次/分。面色苍白,皮肤潮湿多汗。血压:右上肢180/130mmHg,左上肢180/140mmHg,颈动脉未闻及杂音,双肺呼吸音粗,心率110次/分,心尖搏动位于左锁骨中心第5肋交界处,肝脾肋下未触及,腹部未闻及血管杂音,脊柱四肢未见异常。

辅助检查

入院后完善相关检查检验:血常规:白细胞10.78×109/L;生化:血糖15.34mmol/L,肌酐57.0μmol/L,尿素氮4.30mmol/L,甘油三酯2.0mmol/L,总胆固醇6.06mmol/L,低密度脂蛋白3.22mmol/L;卧位血浆肾素>12.0ng/(ml·h)[参考值0.05~0.79ng/(ml·h)],血管紧张素Ⅱ:258.46pg/ml(参考值:55.3~115.3pg/ml),醛固酮:3.6ng/ml(参考值0.065~0.296ng/ml);心电图:窦性心动过速;X线胸片:主动脉结宽,弓降部迂曲,心胸比0.55;心脏超声:左房前后径29mm、左室舒张末径40mm,左室后壁10mm,左室射血分数52%。

入院诊断

①急进型高血压(原因待查)高血压脑病;②2型糖尿病;③高脂血症。

诊治经过与诊治思维

1.简要治疗经过

转入高血压中心后继续乌拉地尔静脉泵入,逐渐减量至停用,同时给予酚苄明15m.q8h口服,酒石酸美托洛尔50m.bid口服,血压维持在140~150/ 80~90mmHg,心率维持在90~110次/分,给予二甲双胍0.5.bid,格列吡嗪2.5m.tid控制血糖,阿托伐他汀20m.qn降脂治疗。

2.科室疑难病例讨论

病例特点:中年女性,持续性血压升高,阵发性加剧,伴反复晕厥、头痛、心悸,大汗。血压最高达250/150mmHg,心率170次/分,多种降压药物大剂量应用,血压控制不良,给予硝普钠静脉泵入后血压无明显下降,而给予盐酸乌拉地尔静脉泵入及酚苄明口服后血压可控制在140~150/80~90mmHg。综上所述,考虑“嗜铬细胞瘤”可能性大,进一步完善相关检查,血肾上腺素0.42ng/ml(参考值:0.02~0.08ng/ml),去甲肾上腺素23.624ng/ml(参考值:0.104~0.548ng/ml);肾上腺CT:左肾上腺增生,肾上腺原位未提示嗜铬细胞瘤,考虑存在异位嗜铬细胞瘤的可能,行腔静脉分段取血确定嗜铬细胞瘤可能位置:左肾水平去甲肾上腺素最高147.690ng/ml(参考值:0.104~0.548ng/ml),故行腹部磁共振检查提示左肾前下方腹主动脉左侧见一4cm×5cm大小类圆形软组织,T1相呈中等偏低信号,T2相信号明显不均匀,中心区域见较高信号影,注入对比剂后见其周围区域强化,中心区域无强化,提示液化坏死性改变,考虑为肾上腺外嗜铬细胞瘤。

3.补充诊断及治疗

补充诊断:

异位嗜铬细胞.继发性高血压;2型糖尿病;高脂血症。

治疗:

给予酚苄明、阿替洛尔控制血压及心率,格列齐特、二甲双胍降糖,阿托伐他汀降脂。血压维持在140~150/80~90mmHg,建议患者维持血压平稳5周后行外科手术切除占位病变,患者因经济原因未进一步手术治疗。

专家点评

本例患者“4P”症状典型,血压持续升高阵发性加剧,反复一过性晕厥,应尽早考虑“嗜铬细胞瘤”的诊断,辅助检查提示血儿茶酚胺显著升高(血肾上腺素高于正常值5倍,去甲肾上腺素高于正常值43倍),但肾上腺CT结果不符合嗜铬细胞瘤的影像学特点,应考虑“异位嗜铬细胞瘤”的可能,进一步行腔静脉分段取血发现左肾水平去甲肾上腺素高于正常80倍,且磁共振于左肾前下方发现信号不均匀占位,故结合症状、体征、实验室检查及影像学检查,“异位嗜铬细胞瘤”诊断成立。

综合分析患者病情,血压在持续升高的基础上阵发性加剧与一过性血浆儿茶酚胺升高有关,而血压急剧升高导致脑血管痉挛,出现反复一过性晕厥;患者血糖升高,原因为血中高浓度的儿茶酚胺可加速糖原分解,促进糖异生,作用于胰岛α受体使胰岛素分泌减少,拮抗胰岛素的降糖作用,从而引起血糖升高。此外,该患者肾素、血管紧张素Ⅱ、醛固酮浓度均较正常值明显升高,考虑为血儿茶酚胺浓度升高启动肾素-血管紧张素-醛固酮系统所致。

临床遇到发作性血压升高、晕厥,合并糖尿病者,应高度怀疑嗜铬细胞瘤的可能性,需谨慎应用血管扩张剂(如钙拮抗剂和硝普钠),而应用α受体阻滞剂更为安全有效。β受体阻滞剂应在α受体阻滞剂的基础上加用。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1747875, encodeId=76ed1e4787567, content=<a href='/topic/show?id=3631990929c' target=_blank style='color:#2F92EE;'>#静注#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99092, encryptionId=3631990929c, topicName=静注)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e635973378, createdName=dangious, createdTime=Fri Nov 23 19:34:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301677, encodeId=fe0d3016e78d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Sun Apr 01 08:32:37 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630328, encodeId=fde3163032866, content=<a href='/topic/show?id=2979e3534a6' target=_blank style='color:#2F92EE;'>#硝普钠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73534, encryptionId=2979e3534a6, topicName=硝普钠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2a721492838, createdName=xuruicheng, createdTime=Sat Mar 31 09:34:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301162, encodeId=337f301162d8, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90e71967716, createdName=易彭, createdTime=Fri Mar 30 09:42:07 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300903, encodeId=16c4300903c4, content=谢谢分享学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Mar 29 18:56:02 CST 2018, time=2018-03-29, status=1, ipAttribution=)]
    2018-11-23 dangious
  2. [GetPortalCommentsPageByObjectIdResponse(id=1747875, encodeId=76ed1e4787567, content=<a href='/topic/show?id=3631990929c' target=_blank style='color:#2F92EE;'>#静注#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99092, encryptionId=3631990929c, topicName=静注)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e635973378, createdName=dangious, createdTime=Fri Nov 23 19:34:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301677, encodeId=fe0d3016e78d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Sun Apr 01 08:32:37 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630328, encodeId=fde3163032866, content=<a href='/topic/show?id=2979e3534a6' target=_blank style='color:#2F92EE;'>#硝普钠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73534, encryptionId=2979e3534a6, topicName=硝普钠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2a721492838, createdName=xuruicheng, createdTime=Sat Mar 31 09:34:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301162, encodeId=337f301162d8, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90e71967716, createdName=易彭, createdTime=Fri Mar 30 09:42:07 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300903, encodeId=16c4300903c4, content=谢谢分享学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Mar 29 18:56:02 CST 2018, time=2018-03-29, status=1, ipAttribution=)]
    2018-04-01 yfjms

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1747875, encodeId=76ed1e4787567, content=<a href='/topic/show?id=3631990929c' target=_blank style='color:#2F92EE;'>#静注#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99092, encryptionId=3631990929c, topicName=静注)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e635973378, createdName=dangious, createdTime=Fri Nov 23 19:34:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301677, encodeId=fe0d3016e78d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Sun Apr 01 08:32:37 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630328, encodeId=fde3163032866, content=<a href='/topic/show?id=2979e3534a6' target=_blank style='color:#2F92EE;'>#硝普钠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73534, encryptionId=2979e3534a6, topicName=硝普钠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2a721492838, createdName=xuruicheng, createdTime=Sat Mar 31 09:34:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301162, encodeId=337f301162d8, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90e71967716, createdName=易彭, createdTime=Fri Mar 30 09:42:07 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300903, encodeId=16c4300903c4, content=谢谢分享学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Mar 29 18:56:02 CST 2018, time=2018-03-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1747875, encodeId=76ed1e4787567, content=<a href='/topic/show?id=3631990929c' target=_blank style='color:#2F92EE;'>#静注#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99092, encryptionId=3631990929c, topicName=静注)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e635973378, createdName=dangious, createdTime=Fri Nov 23 19:34:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301677, encodeId=fe0d3016e78d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Sun Apr 01 08:32:37 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630328, encodeId=fde3163032866, content=<a href='/topic/show?id=2979e3534a6' target=_blank style='color:#2F92EE;'>#硝普钠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73534, encryptionId=2979e3534a6, topicName=硝普钠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2a721492838, createdName=xuruicheng, createdTime=Sat Mar 31 09:34:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301162, encodeId=337f301162d8, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90e71967716, createdName=易彭, createdTime=Fri Mar 30 09:42:07 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300903, encodeId=16c4300903c4, content=谢谢分享学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Mar 29 18:56:02 CST 2018, time=2018-03-29, status=1, ipAttribution=)]
    2018-03-30 易彭

    谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1747875, encodeId=76ed1e4787567, content=<a href='/topic/show?id=3631990929c' target=_blank style='color:#2F92EE;'>#静注#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99092, encryptionId=3631990929c, topicName=静注)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e635973378, createdName=dangious, createdTime=Fri Nov 23 19:34:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301677, encodeId=fe0d3016e78d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Sun Apr 01 08:32:37 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630328, encodeId=fde3163032866, content=<a href='/topic/show?id=2979e3534a6' target=_blank style='color:#2F92EE;'>#硝普钠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73534, encryptionId=2979e3534a6, topicName=硝普钠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2a721492838, createdName=xuruicheng, createdTime=Sat Mar 31 09:34:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301162, encodeId=337f301162d8, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90e71967716, createdName=易彭, createdTime=Fri Mar 30 09:42:07 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300903, encodeId=16c4300903c4, content=谢谢分享学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu Mar 29 18:56:02 CST 2018, time=2018-03-29, status=1, ipAttribution=)]
    2018-03-29 虈亣靌

    谢谢分享学习一下

    0

相关资讯

JACC:硝普钠会对LGSAS和保留EF患者产生哪些影响?

2017年9月,发表在《J Am Coll Cardiol》上的一项研究,调查了低梯度重度主动脉瓣狭窄(LGSAS)伴保留射血分数(EF)患者对硝普钠的急性血流动力学应答,研究结果表明:硝普钠可降低LGSAS伴保留EF患者的动脉后负荷和左心室充盈压,使得25%的患者重新分类为中度狭窄。

JACC:硝普钠可以改善重度主动脉瓣狭窄患者的血流动力学水平

低梯度的重度主动脉瓣狭窄(LGSAS)伴保留型射血分数的病理机制尚未阐明,近日,在国际心血管权威杂志JACC上发表了一篇旨在硝普钠对LGSAS伴保留型射血分数患者的急性血流动力学影响的研究。本研究纳入了41例有临床症状的LGSAS伴保留型射血分数的患者(25例低血流[LF],SVI≤35 ml/m2;16例血流正常[NF]),并在接受硝普钠治疗前后对其血流动力学水平进行评估。在随访开始时,LF患者

曾庆平:二甲双胍,为何能成为长寿灵丹?

二甲双胍(metformin)是著名的降糖药,主要用来治疗2型糖尿病,但它对非酒精性脂肪肝病及癌症等多种人类疾病也有潜在治疗效果。更神奇的是,二甲双胍像热量限制一样能够延长生物的寿命,这已在线虫、大鼠和小鼠中得到证实。如此说来,二甲双胍堪称“神药”、“仙丹”! 6月2日,Science Daily网站报道了《美国科学院院报》(PNAS)刚刚在线发表的一篇最新论文,揭示二甲双胍通过“线粒体低毒

实用:泵药物的配置公式

        硝酸甘油 50mg + NS40ml 0.6ml/h (10ug/min)         硝普钠 50mg + NS 50ml 0.6ml/h (10ug/min)    

Medpage:在硝酸甘油短缺的日子里

硝酸甘油短缺问题上个月一直在困扰着美国新泽西州 Awad博士和他的急诊团队。 Awad博士在接受MedPage Today采访时表示,“静脉注射硝酸甘油是我们治疗心肌梗死、高血压危象和急性失代偿性心力衰竭的主力药物。而且静脉注射硝酸甘油的替代药物很少,现存的替代药多与不良事件相关。” 现在急诊部正面临着一场噩梦:制作商货源短缺削弱了硝酸甘油供应,使得美国许多急诊研究

急性心力衰竭內枓冶疗现状与展望

急性心力衰竭(AHF)是指由于心脏结构或功能的异常,引起心排量的急剧降低,导致组织器官低灌注和急性淤血的一组临床综合征。临床上以急性左心衰最为常见,急性右心衰则较少见,但两者都常危及生命,必须紧急施救和治疗。值得注意的是,近来AHF病人中舒张性心力衰竭(心衰)的比例正逐年增加,尤其是在>65岁的老年人中:其预后并非以往所认为的舒张性心衰病人的预后好于收缩性心衰,而是相似。因此,对广大